NASDAQ: XERS
Xeris Biopharma Holdings, Inc.
Healthcare · Biotechnology
After hours: $8.70(0%) · as of 7:30 PM ET
Market Cap
$1.50B
52w High
$10.08
52w Low
$5.25
P/E
2,712.75
Volume
1.46M
Outstanding Shares
172.64M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 14.62% over the last year. Revenue grew 36.33% over the trailing twelve months. Operating margin moved from -3.99% to 10.91%. Free cash flow grew 430.06% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 48th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at 10.91%. Revenue grew 36.33% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
10
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q4 FY26 · EPS est $0.02 · Revenue est $101.56M
View